Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: A retrospective multicenter outcome assessment in patient routine care

Journal of Neural Transmission

Volumn 120, Issue 11, 2013, Pages 1553-1558

  Antonini, A ^a,b   Odin, P ^c,d   Opiano, L ^e   Tomantschger, V ^f   Pacchetti, C ^g   Pickut, B ^h,i   Gasser, U E ^j   Calandrella, D ^a,b   Mancini, F ^a,b   Zibetti, M ^e   Minafra, B ^g   Bertaina, I ^g   De Deyn, P ^h,i   Cras, C ^h,i   Wolf, E ^k   Spielberger, S ^k   Poewe, W ^k  

^a IRCCS SAN CAMILLO HOSPITAL   (Italy)

^b San Pio X Institute   (Italy)

^c Klinikum Bremerhaven Reinkenheide   (Germany)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e MOLINETTE HOSPITAL   (Italy)

^f Gailtal Klinik   (Austria)

^g C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

^j ClinResearch Ltd   (Switzerland)

^k UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

more..

Author keywords

Duodenal levodopa infusion; Duodopa; Dyskinesia; Motor complications; Parkinson's disease; Quality of life

Indexed keywords

LEVODOPA;

AGED; ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG INFUSION; DRUG SAFETY; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; HYPERSEXUALITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MOOD DISORDER; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SAFETY; POLYNEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; UNIVERSITY HOSPITAL; WEIGHT REDUCTION;

AGED; ANTIPARKINSON AGENTS; DUODENUM; FEMALE; HUMANS; INFUSIONS, PARENTERAL; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84887243998     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1026-9     Document Type: Article

References (25)

1. Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L. Assessment of efficacy and safety in duodenal levodopa infusion in advanced Parkinson's disease. Rev Neurol 2009 Jan 14
2. Antonini A, Mancini F, Canesi M (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 5:244-246
3. Calne SM (2003) The psychosocial impact of late-stage Parkinson's disease. J Neurosci Nurs 35:306-313
4. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F (2005) Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 20:224-230
5. Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 22:1901-1911
6. Clarke CE et al (2009) Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism and Related Disorders. doi: 10.1016/j.parkreldis.2009.09.005
7. Devos D (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 24:993-1000
8. Eggert K, Schrader C, Hahn M et al (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151-166
9. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa induced dyskinesias. Mov Disord 2007;22:1379-1389; quiz 1523
10. Hemmesch AR, Tickle-Degnen L, Zebrowitz LA (2009) The influence of facial masking and sex on older adults' impressions of individuals with Parkinson's disease. Psychol Aging 24:542-549
11. Honig H, Antonini A, Martinez-Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on non-motor symptoms and quality of life. Mov Disord 24:1468-1474
12. Isacson D, Bingefors K, Kristiansen IS, Nyholm D (2008) Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 118:379-386
13. Kurth MC, Tetrud JW, Tanner CM et al (1993) Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 43:1698-1703
14. Meiler B, Andrich J, Müller T (2008) Efficacy evaluation of rapid direct replacement of oral anti-parkinsonism treatment with duodenal levodopa infusion. Mov Disord 23(1):145-146
15. Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 104:343-348
16. Nyholm D (2005) Nilsson Remahl AI, Dizdar N. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216-223
17. Nyholm D (2006) Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 6:1403-1411
18. Nyholm, D, Askmark, H, Gomes-Trolin C, Knutson T, Lennernäs H, Nyström C, Aquilonius SM. Clinic Pharmacokinetic study comparing continuous intraduodenal levodopa infusion and oral levodopa/carbidopa in patients with advanced PD and with severe motor fluctuations. Neuropharmacol 2003;26:156-163 and Study Report NPP-001-99
19. Nyholm D, Lennernäs H, Gomes-Trolin C, Aquilonius SM (2002) Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 25:89-96
20. Nyholm D, Lewander T, Johansson A, LeWitt P, Lundqvist C, Aquilonius SM (2008) Long-term assessment of safety in patients treated with Duodopa. Clin Neuropharmacol 31:63-73
21. Puente V, De Fabregues O, Oliveras C, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord. 2009 Sep 15. [Epub ahead of print] doi: 10.1016/j.parkreldis.2009. 07.015
22. ®): report of six patients. Neurol Sci 30:85-86
23. Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, Odin P, Antonini A, Chaudhuri KR (2012) Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol 35(5):205-207
24. Schapira AH (2007) Treatment options in the modern management of Parkinson disease. Arch Neurol 64:1083-1088
25. Scott B, Borgman A, Engler H, Johnels B, Aquilonius SM (2000) Gender differences in Parkinson's disease symptom profile. Acta Neurol Scand 102:37-43